Apr 13, 2016

Posted by in Biotech Stocks | 0 Comments

Investor’s Alert: aTyr Pharma Inc (NASDAQ:LIFE), Galena Biopharma Inc (NASDAQ:GALE), PDL BioPharma Inc (NASDAQ:PDLI)

Investor’s Alert: aTyr Pharma Inc (NASDAQ:LIFE), Galena Biopharma Inc (NASDAQ:GALE), PDL BioPharma Inc (NASDAQ:PDLI)

aTyr Pharma Inc (NASDAQ:LIFE) stock is at $3.87, up +6.91 percent from its previous close of $3.62. The stock opened the session at $3.70 and touched its highest price point at $3.90. The company’s stock’s lowest price point for the session stood at $3.45. Its yesterday’s volume was 1.76 million shares in comparison to its usual trading volume of 467,140.00 shares.

aTyr Pharma Inc (NASDAQ:LIFE) on March 30, 2016 announced operating results for the fourth quarter and year ended December 31, 2015.

Research and development expenses were $12.7 million and $4.3 million for the quarters ended December 31, 2015 and 2014, respectively. The increase of $8.4 million was primarily due to an additional $6.5 million related to manufacturing costs and clinical development incurred in support of various activities for Resolaris™ and a $1.6 million increase related to compensation expenses resulting from increased headcount in research and development functions, including $1.0 million in non-cash stock-based compensation.

General and administrative expenses were $3.8 million and $1.7 million for the quarters ended December 31, 2015 and 2014, respectively.  The increase of $2.1 million was due primarily to a $1.9 million increase in personnel costs resulting from increased headcount, including $0.3 million in non-cash stock-based compensation.

Research and development expenses for the year ended December 31, 2015 and 2014 were $34.5 million and $16.8 million, respectively. The increase of $17.7 million was due primarily to a $11.4 million increase related to manufacturing costs and clinical development incurred in support of various activities for Resolaris; a $4.1 million increase related to compensation expenses, including $2.0 million of non-cash stock-based compensation expense; and a one-time $1.4 million non-cash expense for the assignment of certain intellectual property rights.

General and administrative expenses were $13.1 million and $6.8 million for the year ended December 31, 2015 and 2014, respectively. The increase of $6.3 million was due primarily to a $3.8 million increase in personnel costs resulting from increased headcount, including $1.1 million in stock-based compensation; a $1.7 million increase in public company costs and a $0.3 million increase in intellectual property-related projects.

Net loss for the year ended December 31, 2015 was $48.0 million, as compared to $ 24.4 million for the same period in 2014.

Galena Biopharma Inc (NASDAQ:GALE) stock is at $1.54, down -1.28 percent from its previous close of $1.56. Its yesterday’s volume was 1.75 million shares in comparison to its usual trading volume of 2.80 million shares. Previous 5 days graph demonstrated a negative move of -7.23%. Its quarterly performance remained green with the percentage of 89.66, while its year to date performance showed that the stock advanced overall 4.05%.

Galena Biopharma Inc (NASDAQ:GALE) announced on March 29, 2016, that the 70th qualifying disease free survival (DFS) event has been achieved in the NeuVax™ (nelipepimut-S) Phase 3, PRESENT (Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. NeuVax is a peptide immunotherapy vaccine currently being evaluated for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials.

For the PRESENT trial, a qualifying DFS event is defined as: a recurrence of the primary breast cancer, either locally in the breast, regionally in the lymph nodes, or distantly as metastatic disease; an occurrence of another cancer; or, death from any cause. All qualifying DFS events are confirmed by the EAC. The IDMC is comprised of two medical oncologists, one cardiologist, and one statistician and will perform the Interim Analysis.

PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) is an international, Phase 3 study to evaluate NeuVax plus granulocyte macrophage-colony stimulating factor (GM-CSF) versus placebo plus GM-CSF to prevent cancer recurrence.  The trial is being run under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). PRESENT is targeting patients who are node positive, HER2 IHC 1+/2+, and HLA A2+ and/or A3+.  The study is double blind, randomized 1:1, and is stratified by stage, type of surgery, hormone receptor status, and menopausal status. Galena enrolled a total of 758 patients who constitute the Intention to Treat (ITT) population, and the primary endpoint for the trial is disease free survival (DFS) upon reaching 141 events with 3 years minimum follow-up.

PDL BioPharma Inc (NASDAQ:PDLI) traded in the range of $3.31 and $3.48 in its previous trading session. The stock recorded the volume of 1.60 million shares so far, in comparison its average daily trading volume of 2.67 million shares. Company’s year to date performance remained declining as it lost almost -2.94%. The stock opened at $3.35 and its closing price for the day was $3.47, up +3.58 percent from its previous close.

PDL BioPharma Inc (NASDAQ:PDLI) on March 31, 2016 announced that the Company will hold its annual meeting of stockholders on Thursday, June 2, 2016, at 10:00 a.m. Pacific Time for all stockholders of record on April 8, 2016. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors.

 

Comments are closed.